Alle Nachrichten zur ISIS PHARMACEUTICALS Aktie | ISIS PHARMACEUTICALS News

DAX	6.050	-3,4%	Dow	12.119	-2,2%	Euro	1,2432	0,6%
ESt50	2.069	-2,4%	Nas	2.748	-2,8%	Öl	98,82	-2,8%
TDax	730,9	-2,7%	Nikkei	8.440	-1,2%	Gold	1.626	4,2%

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Depot
Times + Sales	Chart-Analyse	Analysen	Dividende/HV	Profil	Optionsscheine	Watchlist
Börsenplätze	Chartvergleich	Kursziele		Insidertrades	Knock-outs	myHome
Orderbuch	Realtime Stuttgart	RSS Feed	Analyse	im Forum	Fonds	Senden
Historisch	Realtime Push	myNews neu		IR-Daten	Anleihen	handeln

Sprache:
Alle
DE
EN

Sortieren:
Datum
meistgelesen

27.02.12	DAX schließt auf Freitagsniveau -- S&P senkt Ausblick von EFSF-Rating auf negativ -- Wall Street tritt auf der Stelle -- Deutsche Bank sucht neuen Amerika-Chef -- HSBC, Gerry Weber, Lowe's im Fokus (finanzen.net) Spanien verfehlt Defizitziel für 2011. Euro unter 1,34 US-Dollar. Peugeot will General Motors (GM) verkaufen. Q-Cells ringt weiter um Zahlungsaufschub. GdF droht mit Solidarstreik der Fluglotsen. mehr
22.06.10	Sanofi-Aventis schließt Allianz mit Regulus Therapeutics (Aktiencheck)
29.03.10	Regulus Therapeutics and Collaborators Publish Pre-clinical In Vivo Efficacy Data on microRNA Therapeutics targeting microRNA-10b in Models of Breast Cancer Metastasis (Businesswire)
17.03.10	Regulus Announces U.S. Allowance of Stanford Patent Application Covering miR-181a Function in Immune Cells (Businesswire)
25.01.10	Regulus, Alnylam and Isis Announce U.S. Allowance of Tuschl III Patent Application Covering miR-21 (Businesswire)
15.01.10	Regulus Therapeutics Present New Pre-clinical Data from Multiple Therapeutic Programs at Keystone Symposium (Businesswire)
11.01.10	Regulus Therapeutics Appoints Zachary A. Zimmerman, Ph.D., Director of Business Development (Businesswire)
17.12.09	Regulus Therapeutics Receives Exclusive License for Intellectual Property on Immuno-inflammatory microRNAs from the California Institute of Technology (Businesswire)
09.12.09	Regulus Therapeutics Inc. presents: "MicroRNA: The Year in Review and a Look Ahead” (Businesswire)
28.10.09	Regulus Announces U.S. Allowance of Fundamental microRNA Therapeutics Patent Application (Businesswire)
17.09.09	Regulus, Alnylam, and Isis Announce First microRNA Patent Grant in Japan from Tuschl III Patent Series (Businesswire)
16.09.09	Regulus Therapeutics Appoints Hubert C. Chen, M.D., Vice President of Translational Medicine (Businesswire)
11.08.09	Alnylam and Regulus Receive Notice of Allowance from United States Patent and Trademark Office for New Patent Covering microRNA Therapeutics (Businesswire)
14.05.09	Regulus Therapeutics Achieves Initial Milestone in its Inflammatory Diseases Collaboration with GlaxoSmithKline (Businesswire)
29.04.09	Isis and Alnylam Form New Collaboration to Develop Single-Stranded RNAi Technology (Businesswire)
04.03.09	Regulus Therapeutics Receives $20 Million in a Series A Equity Financing (Businesswire)
04.03.09	Regulus Therapeutics Receives $20 Million in a Series A Equity Financing (Businesswire)
17.12.08	Abbott Laboratories gibt Übernahme bekannt (Aktiencheck)
30.11.08	Regulus Therapeutics, Alnylam Pharmaceuticals, and Collaborators Publish First Ever In Vivo Efficacy Data for a microRNA Therapeutic in a Disease Model (Businesswire)
06.11.08	Regulus Therapeutics and Collaborators Discover Role of a microRNA in Tumor Angiogenesis (Businesswire)
03.09.08	Regulus Therapeutics Appoints Dr. Stelios Papadopoulos to Board of Directors (Businesswire)
19.08.08	Regulus Therapeutics and Collaborators Publish New Data on a Critical Role for miR-21 in Brain Tumors (Businesswire)
04.08.08	Regulus Therapeutics Appoints Garry Menzel, Ph.D., as Executive Vice President Corporate Development and Finance (Businesswire)
24.06.08	Regulus Therapeutics Selected for Fierce 15 Top Biotech Companies (Businesswire)
06.05.08	Regulus Therapeutics Exclusively Licenses Intellectual Property from Stanford University Relating to microRNA Antagonists to Treat Inflammatory Diseases (Businesswire)
11.02.08	Regulus Therapeutics Appoints Peter S. Linsley, Ph.D. as Chief Scientific Officer (Businesswire)
12.12.07	Regulus Therapeutics and Collaborators Discover Role of Viral microRNAs in Cancer and Identify First-Ever Example of a Viral microRNA Oncogene (Businesswire)
03.12.07	Regulus Therapeutics Appoints Kleanthis G. Xanthopoulos, Ph.D. as President and Chief Executive Officer (Businesswire)
19.11.07	Regulus Therapeutics Announces Allowance of Key Patent on microRNA Therapeutics for the Treatment of Hepatitis C Virus Infection (Businesswire)
25.10.07	Regulus Therapeutics and Collaborators Announce Publication of New Research on the Role of microRNAs in Regulating Pathways of Viral Infection (Businesswire)
07.09.07	Isis and Alnylam Launch Regulus Therapeutics, a Joint Venture to Discover, Develop, and Commercialize microRNA Therapeutics (Businesswire)
07.08.07	Archemix and Isis Pharmaceuticals Form Strategic Alliance for Aptamer Drug Discovery and Development (Businesswire)
27.06.07	Alnylam Announces Achievement of Key Milestone in Collaboration Agreement (Businesswire)

Finanzen.net

ISIS Pharmaceuticals Aktie [WKN: 881866 / ISIN: US4643301090]

Nachrichten zu ISIS Pharmaceuticals Inc.

Newssuche

Meistgelesene ISIS Pharmaceuticals News 1M

ISIS Pharmaceuticals Peer Group News